retatrutide phase 2 trial type 2 diabetes weight loss 2024 Retatrutide: A Promising Option for Non-Diabetic in Clinical Trials Eli Lilly infiltrates anti-obesity market

Weight loss can vary widely among individuals, but many people lose between 5% to 10% of their body weight over six months to a year

Management strategies include smaller frequent meals, texture modifications, adequate hydration, and gradual dose titration under medical supervision

All products are supplied for research use only (RUO) and are not intended for human consumption

Phase 3 trials are ongoing and retatrutide remains unapproved for routine clinical use

Retatrutide has demonstrated the highest weight loss potential in clinical trials, with up to 28.7% mean body weight loss at 68 weeks

The strategies that work during month one may not be exactly what you need at month six or month twelve